Novel Targeted Agents In Combination With R-ice (r-ice-x) Based On Genotyping In Relapsed/refractory Dlbcl

At the time of data cut off, a total of 76 patients were enrolled, with a median age of 61 (20–75) years. Among71 patients who completed treatment, the end of induction CR rate was 59.2%, and ORR was 78.9%. In thepatients with R-ICE-zanubrutinib group (n=34), the ORR was 78.8%, with 18 patients (18/33, 54.6%) achievedCR and 8 patients (8/33, 24.2%) achieved PR. The 1-year PFS rate and OS rate were 70.2% and 86.5%,respectively. In the patients with lenalidomide combined with R-ICE (n=30), 17 patients (17/30, 56.7%)achieved CR, 6 (6/30, 20.0%) patients achieved PR, and the ORR was 76.7%. The 1-year PFS and OS rates were84.0% and 100.0%, respectively. 5 patients (5/8, 62.5%) with decitabine plus R-ICE achieved CR. 2 patientsreceived R-ICE-chidamide and got CR as well. Only one patient in R-ICE-tofacitinib considered other clinicalstudies due to poor treatment efficacy. Furthermore, we found the proportion of SOCS1 mutation wasincreased in patients with poor response to R-ICE-X regimen. In univariate analysis, we also revealed that CD70,SOCS1 and TMSB4X mutations indicated poor survival outcomes. Subsequent analyses of poor prognosisgenes in each treatment group will be performed